A Pharmacological Update and Safety Analysis of Medications for Smoking Cessation: Which Ones to Use?

Read full text
Authors: Canan Akman, Feride Sinem Akgün, Betül Akbuğa Özel, Bilgen Özkaya, Göksu Afacan, Ozgur Karcioglu
Cited by: 0
References: 67

Abstract

Interventions to reduce smoking prevalence aim to help patients quit smoking to cut down its hazards and related impairments in human beings. Pharmacological treatments are recommended for those with high levels of addiction because of severe physical and psychological dependence. Use of pharmacotherapy can double the odds of successful quitting. Nicotine replacement therapy (NRT), drug treatment regimens including nicotinic receptor agonists (varenicline), dopamine and norepinephrine reuptake inhibitors (bupropion), cytisinicline (cytisine), and combination therapy (NRT + medication) can be employed on a case-by-case basis. Furthermore, varenicline has been found to be more effective than the other agents in most studies. The most common adverse effects of pharmacological agents include depression, nausea, anxiety, abnormal dreams, and insomnia. On the other hand, electronic cigarettes offer another alternative to aid in smoking cessation (SC). Endurance of SC is mostly related to the employment of combined approaches, such as counselling and pharmacotherapy. This study is designed to provide an up-to-date overview of the contemporary approach to interventions aimed at helping patients in SC.

Fields of Study & Subjects

Smoking Behavior and Cessation Nicotinic Acetylcholine Receptors Study Substance Abuse Treatment and Outcomes

Publication details

Journal / source
Current Pharmaceutical Design
Publisher
Bentham Science Publishers Ltd.
Volume
32
Issue
23
Pages
1789–1797
Publication date
5 January 2026
Language
EN